A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

NCT05332574 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
Other Solid Tumors

Interventions

BIOLOGICAL: GB263T

Sponsor

Genor Biopharma Co., Ltd.